Compare TACT & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TACT | LTRN |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.1M | 49.9M |
| IPO Year | 1996 | 2020 |
| Metric | TACT | LTRN |
|---|---|---|
| Price | $4.29 | $3.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $25.00 |
| AVG Volume (30 Days) | 58.3K | ★ 70.7K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,258,000.00 | N/A |
| Revenue This Year | $21.67 | N/A |
| Revenue Next Year | $7.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.27 | N/A |
| 52 Week Low | $3.12 | $2.55 |
| 52 Week High | $5.70 | $6.12 |
| Indicator | TACT | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 42.82 | 47.80 |
| Support Level | $4.37 | $3.72 |
| Resistance Level | $4.61 | $3.98 |
| Average True Range (ATR) | 0.19 | 0.27 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 19.64 | 48.72 |
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.